FR2498192A2 - Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications - Google Patents
Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications Download PDFInfo
- Publication number
- FR2498192A2 FR2498192A2 FR8101176A FR8101176A FR2498192A2 FR 2498192 A2 FR2498192 A2 FR 2498192A2 FR 8101176 A FR8101176 A FR 8101176A FR 8101176 A FR8101176 A FR 8101176A FR 2498192 A2 FR2498192 A2 FR 2498192A2
- Authority
- FR
- France
- Prior art keywords
- fragment
- iic
- drug
- thiolated
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000008569 process Effects 0.000 title claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 title claims description 39
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 39
- 239000003053 toxin Substances 0.000 title abstract description 12
- 231100000765 toxin Toxicity 0.000 title abstract description 12
- -1 THIOLE COMPOUND Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 17
- 230000001962 neuropharmacologic effect Effects 0.000 claims abstract description 10
- 239000003550 marker Substances 0.000 claims abstract description 8
- 210000002569 neuron Anatomy 0.000 claims abstract description 6
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 31
- 229940118376 tetanus toxin Drugs 0.000 claims description 31
- 238000006177 thiolation reaction Methods 0.000 claims description 19
- 238000010168 coupling process Methods 0.000 claims description 15
- 230000032258 transport Effects 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 7
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 125000005414 dithiopyridyl group Chemical group 0.000 claims description 6
- 230000007441 retrograde transport Effects 0.000 claims description 6
- 230000002427 irreversible effect Effects 0.000 claims description 5
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 4
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- 229960004753 citiolone Drugs 0.000 claims description 3
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 claims description 3
- QXDUMOMMZMHKOH-UHFFFAOYSA-N 2-sulfanylpentanamide Chemical compound CCCC(S)C(N)=O QXDUMOMMZMHKOH-UHFFFAOYSA-N 0.000 claims description 2
- CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 claims description 2
- NRFJZTXWLKPZAV-UHFFFAOYSA-N N-(2-oxo-3-thiolanyl)acetamide Chemical compound CC(=O)NC1CCSC1=O NRFJZTXWLKPZAV-UHFFFAOYSA-N 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 abstract description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000006073 displacement reaction Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 210000002182 synaptic membrane Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003376 axonal effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 230000003565 oculomotor Effects 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 3
- 229940044173 iodine-125 Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002096 anti-tetanic effect Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- NXDSVCJDNFCUBP-UHFFFAOYSA-N 2-sulfanylbutanamide Chemical compound CCC(S)C(N)=O NXDSVCJDNFCUBP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000001935 peptisation Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010001039 tetanus toxin receptor Proteins 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8101176A FR2498192A2 (fr) | 1981-01-22 | 1981-01-22 | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
| ES508935A ES508935A0 (es) | 1981-01-22 | 1982-01-21 | "procedimiento para la obtencion de un compuesto polipeptidico tiolado". |
| DE8282400115T DE3264703D1 (en) | 1981-01-22 | 1982-01-21 | Thiolated polypeptidic compound from a tetanic toxin fragment, process for its production and its applications |
| EP82400115A EP0057140B1 (fr) | 1981-01-22 | 1982-01-21 | Nouveau composé polypeptidique thiolé provenant d'un fragment de la toxine tétanique, son procédé d'obtention et ses applications |
| US06/341,335 US4479940A (en) | 1981-01-22 | 1982-01-21 | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications |
| CA000394587A CA1182811A (en) | 1981-01-22 | 1982-01-21 | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications |
| JP57007770A JPS57176916A (en) | 1981-01-22 | 1982-01-22 | Novel thiolated polypeptide derived from tetanus toxin fragment, preparation and application |
| ES519456A ES519456A0 (es) | 1981-01-22 | 1983-02-01 | Procedimiento de union de un compuesto polipeptidico tiolado con una sustancia activa. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8101176A FR2498192A2 (fr) | 1981-01-22 | 1981-01-22 | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2498192A2 true FR2498192A2 (fr) | 1982-07-23 |
| FR2498192B2 FR2498192B2 (member.php) | 1983-09-09 |
Family
ID=9254407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8101176A Granted FR2498192A2 (fr) | 1981-01-22 | 1981-01-22 | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4479940A (member.php) |
| EP (1) | EP0057140B1 (member.php) |
| JP (1) | JPS57176916A (member.php) |
| CA (1) | CA1182811A (member.php) |
| DE (1) | DE3264703D1 (member.php) |
| ES (2) | ES508935A0 (member.php) |
| FR (1) | FR2498192A2 (member.php) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59116229A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法 |
| JPS59116232A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体及びその製造法 |
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| IL69558A (en) * | 1983-08-23 | 1988-06-30 | Yeda Res & Dev | Synthetic cholera vaccine |
| US4666884A (en) * | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| FR2567521B1 (fr) * | 1984-07-13 | 1987-01-02 | Sanofi Sa | Nouveaux ionophores actives |
| CA1314245C (en) * | 1984-05-23 | 1993-03-09 | Franz Jansen | Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
| US6022950A (en) * | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| FR2575160B1 (fr) * | 1984-12-21 | 1987-03-20 | Sanofi Sa | Composes ionophores carboxyliques monovalents |
| US4762710A (en) * | 1986-06-16 | 1988-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Novel method of preparing toxoid by oxidation and metal ions |
| US5084559A (en) * | 1987-03-27 | 1992-01-28 | Repligen Corporation | Protein a domain mutants |
| US5601826A (en) * | 1989-06-30 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
| US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| GB9020075D0 (en) | 1990-09-14 | 1990-10-24 | Filler Aaron G | Contrast agents for magnetic resonance imaging of axonal transport |
| US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
| US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| EP1681300A1 (en) * | 1997-08-14 | 2006-07-19 | Institut Pasteur | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS |
| US7923216B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
| US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
| US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
| US6258774B1 (en) * | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
| US20070092449A1 (en) * | 2005-04-05 | 2007-04-26 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
| ES2332628B1 (es) * | 2007-10-05 | 2011-01-24 | Universidad De Zaragoza | Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento. |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3171831A (en) * | 1961-02-14 | 1965-03-02 | Schwarz Biores Inc | Thiolation of proteins by reaction with homocysteine thiolactone in the presence of tertiary amine |
| DE1617880A1 (de) * | 1966-10-06 | 1971-07-22 | Karl Dr Med Theurer | Verfahren zur Gewinnung von organotropen,bioaktiven Wirkstoffen,insbesondere von Arzneimitteln |
| BE831786A (fr) * | 1974-10-14 | 1975-11-17 | All India Inst Med | Vaccin contre la gravidite et procede de sa preparation |
| FR2334954A1 (fr) * | 1975-12-12 | 1977-07-08 | Dainippon Pharmaceutical Co | Reactif convenant pour la determination immunologique enzymatique |
| FR2366569A1 (fr) * | 1976-09-29 | 1978-04-28 | Mochida Pharm Co Ltd | Procede immunochimique et reactifs pour le dosage d'haptene |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2938023A (en) * | 1957-04-17 | 1960-05-24 | Hoechst Ag | Manufacture of glutathione containing mercapto groups |
| DE2355094C3 (de) * | 1973-11-03 | 1979-05-23 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tetanus-Impfstoffs |
| US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
| FR2470773B1 (member.php) * | 1979-11-28 | 1983-01-28 | Pasteur Institut | |
| US4284624A (en) * | 1980-05-02 | 1981-08-18 | E. R. Squibb & Sons, Inc. | Mixed disulfides |
-
1981
- 1981-01-22 FR FR8101176A patent/FR2498192A2/fr active Granted
-
1982
- 1982-01-21 CA CA000394587A patent/CA1182811A/en not_active Expired
- 1982-01-21 ES ES508935A patent/ES508935A0/es active Granted
- 1982-01-21 US US06/341,335 patent/US4479940A/en not_active Expired - Fee Related
- 1982-01-21 DE DE8282400115T patent/DE3264703D1/de not_active Expired
- 1982-01-21 EP EP82400115A patent/EP0057140B1/fr not_active Expired
- 1982-01-22 JP JP57007770A patent/JPS57176916A/ja active Pending
-
1983
- 1983-02-01 ES ES519456A patent/ES519456A0/es active Granted
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3171831A (en) * | 1961-02-14 | 1965-03-02 | Schwarz Biores Inc | Thiolation of proteins by reaction with homocysteine thiolactone in the presence of tertiary amine |
| DE1617880A1 (de) * | 1966-10-06 | 1971-07-22 | Karl Dr Med Theurer | Verfahren zur Gewinnung von organotropen,bioaktiven Wirkstoffen,insbesondere von Arzneimitteln |
| BE831786A (fr) * | 1974-10-14 | 1975-11-17 | All India Inst Med | Vaccin contre la gravidite et procede de sa preparation |
| GB1492445A (en) * | 1974-10-14 | 1977-11-16 | All India Inst Med | Immunochemically purified derivatives of human chorionic gonadotropin |
| FR2334954A1 (fr) * | 1975-12-12 | 1977-07-08 | Dainippon Pharmaceutical Co | Reactif convenant pour la determination immunologique enzymatique |
| FR2366569A1 (fr) * | 1976-09-29 | 1978-04-28 | Mochida Pharm Co Ltd | Procede immunochimique et reactifs pour le dosage d'haptene |
Non-Patent Citations (3)
| Title |
|---|
| CA1980 * |
| EXBK/77 * |
| EXBK/78 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8306714A1 (es) | 1983-06-01 |
| EP0057140B1 (fr) | 1985-07-17 |
| EP0057140A3 (en) | 1982-08-25 |
| CA1182811A (en) | 1985-02-19 |
| ES8400736A1 (es) | 1983-11-01 |
| FR2498192B2 (member.php) | 1983-09-09 |
| EP0057140A2 (fr) | 1982-08-04 |
| JPS57176916A (en) | 1982-10-30 |
| US4479940A (en) | 1984-10-30 |
| ES508935A0 (es) | 1983-06-01 |
| DE3264703D1 (en) | 1985-08-22 |
| ES519456A0 (es) | 1983-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2498192A2 (fr) | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications | |
| JP2942356B2 (ja) | 毒素および薬剤を含む治療用複合体 | |
| EP0000938B1 (en) | Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them | |
| CH647411A5 (fr) | Procede de preparation de produits cytotoxiques. | |
| DK166966B1 (da) | Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater | |
| HU189469B (en) | Process for preparing antitumour immunoglobulin-derivatives with antibody effect, comprising ricin a subordinate unit | |
| EP0055115B1 (en) | Cytotoxic protein hybrid and process for the preparation thereof | |
| EP0080401B1 (fr) | Nouveaux médicaments anticancéreux pour le traitement des leucémies T constitués de la chaine A de la ricine et d'un anticorps monoclonal spécifique | |
| JPS61227532A (ja) | 抗体ハイブリツド分子およびその製造方法 | |
| EP0112720B1 (en) | Conjugate having cytotoxicity and process for the preparation thereof | |
| JPS6069033A (ja) | 免疫毒素複合体 | |
| US4594336A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application | |
| JPS6112630A (ja) | 免疫毒素およびその製造法 | |
| JPH064678B2 (ja) | 抗体複合体の製造方法 | |
| CA1183775A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications | |
| EP0065320B1 (fr) | Procédé de couplage d'un médicament avec un composé polypeptidique thiolé provenant d'un fragment de la toxine tétanique et ses applications | |
| FR2577135A1 (fr) | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques | |
| FR2641468A1 (fr) | Anticorps chimeriques anti-recepteur de l'interleukine-2 humaine, leur preparation et compositions pharmaceutiques les contenant | |
| US4582703A (en) | Cytotoxic medicament formed from the association of at least one immunotoxin and chloroquin | |
| FR2701710A1 (fr) | Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic. | |
| US4767621A (en) | Drugs comprising in association at least one immunotoxin and at least one monovalent carboxylic ionophore | |
| EP0162781B1 (fr) | Conjugués associant par liaison covalente un ionophore carboxylique monovalent et une macromolécule, leur utilisation comme agents potentialisateurs des immunotoxines et les ionophores activés intermédiaires | |
| JPH04266829A (ja) | 免疫結合体を形成するための抗体の化学修飾 | |
| FR2759296A1 (fr) | Complexe non-covalent comprenant au moins un anticorps et un element de liaison aux immunoglobulines associe a une substance active, son procede de preparation et ses applications | |
| US20040092723A1 (en) | Compositions and methods for the intracellular delivery of antibodies |